Novo Nordisk A/S (NOVO-B.CO)
| Previous close | 883.20 |
| Open | 900.00 |
| Bid | 905.60 x 0 |
| Ask | 909.90 x 0 |
| Day's range | 891.00 - 909.90 |
| 52-week range | 504.40 - 932.00 |
| Volume | |
| Avg. volume | 2,655,731 |
| Market cap | 4.053T |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | 45.79 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 12.80 (1.45%) |
| Ex-dividend date | 22 Mar 2024 |
| 1y target est | N/A |
- Reuters
UPDATE 2-Denmark faces Wegovy shortage due to rising demand
Denmark faces a supply shortage for two doses of Novo Nordisk's Wegovy weight-loss drug in the coming months due to rising demand, the Danish Medicines Agency said on Monday. The hugely popular Wegovy is given by weekly injection and belongs to a class of drugs known as GLP-1 agonists originally developed to treat type 2 diabetes. There will be a shortage of Novo Nordisk's Wegovy Flextouch 1 milligram pen from late May to mid-June, the Danish medicines agency said in a statement.
- The Telegraph
‘Outrageously’ expensive Ozempic should be cheaper, says Bernie Sanders
Ozempic and Wegovy maker Novo Nordisk should be forced to cut the price of its obesity and diabetes wonder drugs, Bernie Sanders has said, claiming the current costs are “outrageously high”.
- Investor's Business Daily
Is Eli Lilly Stock A Buy Or A Sell As FDA Plans Meeting To Discuss Alzheimer's Drug?
Eli Lilly stock broke out, but then slumped. The FDA is soon to hold a meeting to discuss its Alzheimer's drug. Is LLY stock a buy or a sell?
